glp-1 in type 1 diabetes patients with residual ß-cell function, treatment Ozempic and Other Off-Label Drugs
Description
Backed by 3 powerful mechanisms: GLP-1 Core Act
, & Carlessi, R
Of the patients who took semaglutide and then developed NAION, those aged 40 to 64 (HR=3.31), who were female (HR=3.24), who were white (HR=2.34) or who had hypertension (HR=2.42) were more likely to be affected
Short-term prediction of glucose in type 1 diabetes using kernel adaptive filters
